The Committee of Experts on Vaccine Management under the chairmanship of Dr. VK Paul, a member of NITI Aayog, will meet on Wednesday to discuss the logistical and moral facets of the acquisition and management of the COVID-19 vaccine, the Ministry of Health said. and The Family of the Union.
The Committee will work with all stakeholders, state governments and vaccine manufacturers.
“The Committee of Experts on Vaccine Management, chaired by Dr. V K Paul, NITI Aayog, will meet on 12 August to discuss the logistical and moral facets of the acquisition and management of the COVID19 vaccine,” the ministry tweeted.
“The Committee will have interaction with all stakeholders, adding state governments and vaccine manufacturers,” he said in a tweet.
The Committee will work with all stakeholders, state governments and vaccine manufacturers.
According to the Indian Medical Research Council (ICMR), 3 Indian COVID-19 vaccines are lately in clinical trial stages.
“Right now, we have 3 Indian vaccines that are in other stages of clinical trials. The two vaccines, the Bharat Biotech vaccine and the Zydus Cadila DNA vaccine, have completed Phase 1 and will begin Phase 2, while the third is the Oxford vaccine.” said ICMR chief scientist (professor) Balram Bhargava.
“The Oxford vaccine, manufactured through the Serum Institute of India (SII), was approved for Phase 2 and 3 clinical trials, which begin within a week at 17 sites,” he added.
Listen to the newest songs in JioSaavn.com
The COVID-19 count in India surpassed the 22 lakh mark, adding 6,34,945 active cases, 15,35,744 cured/unloaded/migrated, while the accumulated balance sheet reached 44386.
However, the Ministry of Health noted that the infection is now concentrated in 10 states that contribute to more than 80% of new cases.
Follow the coronavirus pandemic in India and get the latest NEWS about COVID-19 from around the world in ndtv.com/coronavirus
Watch the live:
Follow:
………………………….. Advertising…………………………..